#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=The main finding of our study is that the risk of AKI rose proportionally according to the amount of pRBC and FFP transfusions in both ABO-c and ABO-i LT , but this association of pRBC and FFP transfusions with post-transplant AKI was stronger in ABO-i LT than in ABO-c LT .
3-1	15-18	The	abstract[3]	new[3]	_	_
3-2	19-23	main	abstract[3]	new[3]	_	_
3-3	24-31	finding	abstract[3]	new[3]	_	_
3-4	32-34	of	abstract[3]	new[3]	_	_
3-5	35-38	our	abstract[3]|person|abstract[5]	new[3]|acc|new[5]	ana|coref|ana|coref	5-4|18-22[155_5]|5-4|18-22[155_5]
3-6	39-44	study	abstract[3]|abstract[5]	new[3]|new[5]	_	_
3-7	45-47	is	_	_	_	_
3-8	48-52	that	_	_	_	_
3-9	53-56	the	abstract[6]	new[6]	coref	8-18[0_6]
3-10	57-61	risk	abstract[6]	new[6]	_	_
3-11	62-64	of	abstract[6]	new[6]	_	_
3-12	65-68	AKI	abstract[6]|place	new[6]|new	coref	3-41
3-13	69-73	rose	_	_	_	_
3-14	74-88	proportionally	_	_	_	_
3-15	89-98	according	_	_	_	_
3-16	99-101	to	_	_	_	_
3-17	102-105	the	quantity[8]	new[8]	_	_
3-18	106-112	amount	quantity[8]	new[8]	_	_
3-19	113-115	of	quantity[8]	new[8]	_	_
3-20	116-120	pRBC	quantity[8]|abstract	new[8]|new	coref	3-35
3-21	121-124	and	_	_	_	_
3-22	125-128	FFP	substance|abstract[11]	new|new[11]	coref|coref|coref|coref	3-37|3-37[18_11]|3-37|3-37[18_11]
3-23	129-141	transfusions	abstract[11]	new[11]	_	_
3-24	142-144	in	abstract[11]	new[11]	_	_
3-25	145-149	both	abstract[11]|abstract[12]	new[11]|new[12]	coref	3-49[21_12]
3-26	150-155	ABO-c	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-27	156-159	and	abstract[11]	new[11]	_	_
3-28	160-165	ABO-i	abstract[11]|abstract	new[11]|new	coref	3-45[20_0]
3-29	166-168	LT	abstract[11]|abstract	new[11]|new	coref	4-25
3-30	169-170	,	_	_	_	_
3-31	171-174	but	_	_	_	_
3-32	175-179	this	abstract[15]	new[15]	_	_
3-33	180-191	association	abstract[15]	new[15]	_	_
3-34	192-194	of	abstract[15]	new[15]	_	_
3-35	195-199	pRBC	abstract[15]|abstract	new[15]|giv	coref	16-5
3-36	200-203	and	_	_	_	_
3-37	204-207	FFP	substance|abstract[18]	giv|giv[18]	coref|coref|coref|coref	4-32[33_18]|12-13|4-32[33_18]|12-13
3-38	208-220	transfusions	abstract[18]	giv[18]	_	_
3-39	221-225	with	abstract[18]	giv[18]	_	_
3-40	226-241	post-transplant	abstract[18]	giv[18]	_	_
3-41	242-245	AKI	abstract[18]|place	giv[18]|giv	coref	4-4
3-42	246-249	was	_	_	_	_
3-43	250-258	stronger	_	_	_	_
3-44	259-261	in	_	_	_	_
3-45	262-267	ABO-i	abstract[20]	giv[20]	coref	4-24[0_20]
3-46	268-270	LT	abstract[20]	giv[20]	_	_
3-47	271-275	than	_	_	_	_
3-48	276-278	in	_	_	_	_
3-49	279-284	ABO-c	abstract[21]	giv[21]	coref	6-16[47_21]
3-50	285-287	LT	abstract[21]	giv[21]	_	_
3-51	288-289	.	_	_	_	_

#Text=Given that the AKI rates increased in patients with preoperative anemia and that the influence of transfusion on AKI was more pronounced in ABO-i LT patients , any efforts to reduce perioperative transfusions may protect patients with ABO-i LT against AKI .
4-1	290-295	Given	_	_	_	_
4-2	296-300	that	_	_	_	_
4-3	301-304	the	abstract[23]	new[23]	_	_
4-4	305-308	AKI	place|abstract[23]	giv|new[23]	coref	4-19
4-5	309-314	rates	abstract[23]	new[23]	_	_
4-6	315-324	increased	_	_	_	_
4-7	325-327	in	_	_	_	_
4-8	328-336	patients	person[24]	new[24]	coref	4-24[31_24]
4-9	337-341	with	person[24]	new[24]	_	_
4-10	342-354	preoperative	person[24]|abstract[25]	new[24]|new[25]	_	_
4-11	355-361	anemia	person[24]|abstract[25]	new[24]|new[25]	_	_
4-12	362-365	and	_	_	_	_
4-13	366-370	that	_	_	_	_
4-14	371-374	the	abstract[26]	new[26]	_	_
4-15	375-384	influence	abstract[26]	new[26]	_	_
4-16	385-387	of	abstract[26]	new[26]	_	_
4-17	388-399	transfusion	abstract[26]|abstract	new[26]|new	coref	11-32[93_0]
4-18	400-402	on	abstract[26]	new[26]	_	_
4-19	403-406	AKI	abstract[26]|place	new[26]|giv	coref	4-41
4-20	407-410	was	_	_	_	_
4-21	411-415	more	_	_	_	_
4-22	416-426	pronounced	_	_	_	_
4-23	427-429	in	_	_	_	_
4-24	430-435	ABO-i	abstract|person[31]	giv|giv[31]	coref|coref|coref|coref	4-36[0_31]|4-38[35_0]|4-36[0_31]|4-38[35_0]
4-25	436-438	LT	abstract|person[31]	giv|giv[31]	coref	13-30
4-26	439-447	patients	person[31]	giv[31]	_	_
4-27	448-449	,	_	_	_	_
4-28	450-453	any	event[32]	new[32]	_	_
4-29	454-461	efforts	event[32]	new[32]	_	_
4-30	462-464	to	_	_	_	_
4-31	465-471	reduce	_	_	_	_
4-32	472-485	perioperative	abstract[33]	giv[33]	coref	13-32[118_33]
4-33	486-498	transfusions	abstract[33]	giv[33]	_	_
4-34	499-502	may	_	_	_	_
4-35	503-510	protect	_	_	_	_
4-36	511-519	patients	person	giv	coref	12-3[97_0]
4-37	520-524	with	_	_	_	_
4-38	525-530	ABO-i	abstract[35]	giv[35]	coref	6-7[46_35]
4-39	531-533	LT	abstract[35]	giv[35]	_	_
4-40	534-541	against	_	_	_	_
4-41	542-545	AKI	place	giv	coref	7-13
4-42	546-547	.	_	_	_	_

#Text=However , as our observations were from a retrospective analysis , prospective trials are required to confirm our hypothesis .
5-1	548-555	However	_	_	_	_
5-2	556-557	,	_	_	_	_
5-3	558-560	as	_	_	_	_
5-4	561-564	our	person|abstract[38]	giv|new[38]	ana|ana	5-18|5-18
5-5	565-577	observations	abstract[38]	new[38]	_	_
5-6	578-582	were	_	_	_	_
5-7	583-587	from	_	_	_	_
5-8	588-589	a	abstract[39]	new[39]	coref	21-8[171_39]
5-9	590-603	retrospective	abstract[39]	new[39]	_	_
5-10	604-612	analysis	abstract[39]	new[39]	_	_
5-11	613-614	,	_	_	_	_
5-12	615-626	prospective	event[40]	new[40]	_	_
5-13	627-633	trials	event[40]	new[40]	_	_
5-14	634-637	are	_	_	_	_
5-15	638-646	required	_	_	_	_
5-16	647-649	to	_	_	_	_
5-17	650-657	confirm	_	_	_	_
5-18	658-661	our	person|abstract[42]	giv|new[42]	ana|ana	18-22|18-22
5-19	662-672	hypothesis	abstract[42]	new[42]	_	_
5-20	673-674	.	_	_	_	_

#Text=Patient mortality and graft survival after ABO-i LT have been reported to be comparable to ABO-c LT , although there is still concern regarding the high incidence of antibody-mediated rejection , including biliary stricture related to a high isoagglutinin titer .
6-1	675-682	Patient	event[43]	new[43]	coref	8-7[0_43]
6-2	683-692	mortality	event[43]	new[43]	_	_
6-3	693-696	and	_	_	_	_
6-4	697-702	graft	abstract|event[45]	new|new[45]	coref|coref	8-4|8-4
6-5	703-711	survival	event[45]	new[45]	_	_
6-6	712-717	after	event[45]	new[45]	_	_
6-7	718-723	ABO-i	event[45]|abstract[46]	new[45]|giv[46]	coref	8-23[71_46]
6-8	724-726	LT	event[45]|abstract[46]	new[45]|giv[46]	_	_
6-9	727-731	have	_	_	_	_
6-10	732-736	been	_	_	_	_
6-11	737-745	reported	_	_	_	_
6-12	746-748	to	_	_	_	_
6-13	749-751	be	_	_	_	_
6-14	752-762	comparable	_	_	_	_
6-15	763-765	to	_	_	_	_
6-16	766-771	ABO-c	substance[47]	giv[47]	_	_
6-17	772-774	LT	substance[47]	giv[47]	_	_
6-18	775-776	,	_	_	_	_
6-19	777-785	although	_	_	_	_
6-20	786-791	there	_	_	_	_
6-21	792-794	is	_	_	_	_
6-22	795-800	still	abstract[48]	new[48]	_	_
6-23	801-808	concern	abstract[48]	new[48]	_	_
6-24	809-818	regarding	_	_	_	_
6-25	819-822	the	abstract[49]	new[49]	_	_
6-26	823-827	high	abstract[49]	new[49]	_	_
6-27	828-837	incidence	abstract[49]	new[49]	_	_
6-28	838-840	of	abstract[49]	new[49]	_	_
6-29	841-858	antibody-mediated	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-30	859-868	rejection	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-31	869-870	,	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-32	871-880	including	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-33	881-888	biliary	abstract[49]|abstract[50]|object|object[52]	new[49]|new[50]|new|new[52]	_	_
6-34	889-898	stricture	abstract[49]|abstract[50]|object[52]	new[49]|new[50]|new[52]	_	_
6-35	899-906	related	_	_	_	_
6-36	907-909	to	_	_	_	_
6-37	910-911	a	abstract[53]	new[53]	coref	7-1[55_53]
6-38	912-916	high	abstract[53]	new[53]	_	_
6-39	917-930	isoagglutinin	abstract[53]	new[53]	_	_
6-40	931-936	titer	abstract[53]	new[53]	_	_
6-41	937-938	.	_	_	_	_

#Text=This high isoagglutinin titer may provoke another major organ injury , including AKI , through an immunologic response .
7-1	939-943	This	abstract[55]	giv[55]	coref	9-16[76_55]
7-2	944-948	high	abstract[55]	giv[55]	_	_
7-3	949-962	isoagglutinin	person|abstract[55]	new|giv[55]	coref	9-18
7-4	963-968	titer	abstract[55]	giv[55]	_	_
7-5	969-972	may	_	_	_	_
7-6	973-980	provoke	_	_	_	_
7-7	981-988	another	event[57]	new[57]	coref	10-12[81_57]
7-8	989-994	major	event[57]	new[57]	_	_
7-9	995-1000	organ	abstract|event[57]	new|new[57]	coref	10-9
7-10	1001-1007	injury	event[57]	new[57]	_	_
7-11	1008-1009	,	event[57]	new[57]	_	_
7-12	1010-1019	including	event[57]	new[57]	_	_
7-13	1020-1023	AKI	event[57]|place	new[57]|giv	coref	8-2
7-14	1024-1025	,	_	_	_	_
7-15	1026-1033	through	_	_	_	_
7-16	1034-1036	an	abstract[59]	new[59]	coref	16-11[134_59]
7-17	1037-1048	immunologic	abstract[59]	new[59]	_	_
7-18	1049-1057	response	abstract[59]	new[59]	_	_
7-19	1058-1059	.	_	_	_	_

#Text=As AKI affects graft outcomes and mortality after liver transplantation , it is important to elucidate modifiable risk factors of AKI in ABO-i LT .
8-1	1060-1062	As	_	_	_	_
8-2	1063-1066	AKI	place	giv	coref	8-21[70_0]
8-3	1067-1074	affects	_	_	_	_
8-4	1075-1080	graft	abstract|abstract[62]	giv|new[62]	_	_
8-5	1081-1089	outcomes	abstract[62]	new[62]	_	_
8-6	1090-1093	and	_	_	_	_
8-7	1094-1103	mortality	event	giv	_	_
8-8	1104-1109	after	_	_	_	_
8-9	1110-1115	liver	object|object[65]	new|new[65]	ana|coref|ana|coref	8-12[0_65]|13-16|8-12[0_65]|13-16
8-10	1116-1131	transplantation	object[65]	new[65]	_	_
8-11	1132-1133	,	_	_	_	_
8-12	1134-1136	it	object	giv	coref	11-23
8-13	1137-1139	is	_	_	_	_
8-14	1140-1149	important	_	_	_	_
8-15	1150-1152	to	person[67]	new[67]	_	_
8-16	1153-1162	elucidate	person[67]	new[67]	_	_
8-17	1163-1173	modifiable	person[67]|abstract[69]	new[67]|new[69]	coref	21-6[0_69]
8-18	1174-1178	risk	person[67]|abstract|abstract[69]	new[67]|giv|new[69]	coref	13-8
8-19	1179-1186	factors	person[67]|abstract[69]	new[67]|new[69]	_	_
8-20	1187-1189	of	person[67]|abstract[69]	new[67]|new[69]	_	_
8-21	1190-1193	AKI	person[67]|abstract[69]|place[70]	new[67]|new[69]|giv[70]	coref	9-4[0_70]
8-22	1194-1196	in	person[67]|abstract[69]|place[70]	new[67]|new[69]|giv[70]	_	_
8-23	1197-1202	ABO-i	person[67]|abstract[69]|place[70]|abstract[71]	new[67]|new[69]|giv[70]|giv[71]	coref	9-9[74_71]
8-24	1203-1205	LT	person[67]|abstract[69]|place[70]|abstract[71]	new[67]|new[69]|giv[70]|giv[71]	_	_
8-25	1206-1207	.	_	_	_	_

#Text=The reason why AKI occurs more frequently in ABO-i LT is not certain , although the high isoagglutinin titer may play a role .
9-1	1208-1211	The	abstract[72]	new[72]	_	_
9-2	1212-1218	reason	abstract[72]	new[72]	_	_
9-3	1219-1222	why	_	_	_	_
9-4	1223-1226	AKI	place	giv	coref	13-11[108_0]
9-5	1227-1233	occurs	_	_	_	_
9-6	1234-1238	more	_	_	_	_
9-7	1239-1249	frequently	_	_	_	_
9-8	1250-1252	in	_	_	_	_
9-9	1253-1258	ABO-i	abstract[74]	giv[74]	coref	12-5[98_74]
9-10	1259-1261	LT	abstract[74]	giv[74]	_	_
9-11	1262-1264	is	_	_	_	_
9-12	1265-1268	not	_	_	_	_
9-13	1269-1276	certain	_	_	_	_
9-14	1277-1278	,	_	_	_	_
9-15	1279-1287	although	_	_	_	_
9-16	1288-1291	the	abstract[76]	giv[76]	coref	10-1[78_76]
9-17	1292-1296	high	abstract[76]	giv[76]	_	_
9-18	1297-1310	isoagglutinin	person|abstract[76]	giv|giv[76]	_	_
9-19	1311-1316	titer	abstract[76]	giv[76]	_	_
9-20	1317-1320	may	_	_	_	_
9-21	1321-1325	play	_	_	_	_
9-22	1326-1327	a	abstract[77]	new[77]	_	_
9-23	1328-1332	role	abstract[77]	new[77]	_	_
9-24	1333-1334	.	_	_	_	_

#Text=A high isoagglutinin titer may lead to major organ damage through possible immunologic injury .
10-1	1335-1336	A	abstract[78]	giv[78]	coref	20-15[167_78]
10-2	1337-1341	high	abstract[78]	giv[78]	_	_
10-3	1342-1355	isoagglutinin	abstract[78]	giv[78]	_	_
10-4	1356-1361	titer	abstract[78]	giv[78]	_	_
10-5	1362-1365	may	_	_	_	_
10-6	1366-1370	lead	_	_	_	_
10-7	1371-1373	to	_	_	_	_
10-8	1374-1379	major	abstract[80]	new[80]	_	_
10-9	1380-1385	organ	object|abstract[80]	giv|new[80]	_	_
10-10	1386-1392	damage	abstract[80]	new[80]	_	_
10-11	1393-1400	through	_	_	_	_
10-12	1401-1409	possible	event[81]	giv[81]	_	_
10-13	1410-1421	immunologic	event[81]	giv[81]	_	_
10-14	1422-1428	injury	event[81]	giv[81]	_	_
10-15	1429-1430	.	_	_	_	_

#Text=In addition , the prevalent baseline metabolic alkalosis , low platelet count , and high incidence of mild arterial hypoxemia prior to transplantation surgery may contribute to the high incidence of intraoperative transfusion and low oxygen delivery to the kidney .
11-1	1431-1433	In	_	_	_	_
11-2	1434-1442	addition	_	_	_	_
11-3	1443-1444	,	_	_	_	_
11-4	1445-1448	the	abstract[84]	new[84]	_	_
11-5	1449-1458	prevalent	abstract[84]	new[84]	_	_
11-6	1459-1467	baseline	abstract|abstract[84]	new|new[84]	_	_
11-7	1468-1477	metabolic	person|abstract[84]	new|new[84]	_	_
11-8	1478-1487	alkalosis	abstract[84]	new[84]	_	_
11-9	1488-1489	,	_	_	_	_
11-10	1490-1493	low	abstract[86]	new[86]	_	_
11-11	1494-1502	platelet	object|abstract[86]	new|new[86]	_	_
11-12	1503-1508	count	abstract[86]	new[86]	_	_
11-13	1509-1510	,	_	_	_	_
11-14	1511-1514	and	_	_	_	_
11-15	1515-1519	high	abstract[87]	new[87]	_	_
11-16	1520-1529	incidence	abstract[87]	new[87]	_	_
11-17	1530-1532	of	abstract[87]	new[87]	_	_
11-18	1533-1537	mild	abstract[87]|abstract[89]	new[87]|new[89]	_	_
11-19	1538-1546	arterial	abstract[87]|substance|abstract[89]	new[87]|new|new[89]	_	_
11-20	1547-1556	hypoxemia	abstract[87]|abstract[89]	new[87]|new[89]	_	_
11-21	1557-1562	prior	abstract[87]	new[87]	_	_
11-22	1563-1565	to	abstract[87]	new[87]	_	_
11-23	1566-1581	transplantation	abstract[87]|object|event[91]	new[87]|giv|new[91]	coref|coref|coref|coref	12-20[0_91]|13-16[111_0]|12-20[0_91]|13-16[111_0]
11-24	1582-1589	surgery	abstract[87]|event[91]	new[87]|new[91]	_	_
11-25	1590-1593	may	_	_	_	_
11-26	1594-1604	contribute	_	_	_	_
11-27	1605-1607	to	_	_	_	_
11-28	1608-1611	the	abstract[92]	new[92]	_	_
11-29	1612-1616	high	abstract[92]	new[92]	_	_
11-30	1617-1626	incidence	abstract[92]	new[92]	_	_
11-31	1627-1629	of	abstract[92]	new[92]	_	_
11-32	1630-1644	intraoperative	abstract[92]|abstract[93]	new[92]|giv[93]	coref	12-13[101_93]
11-33	1645-1656	transfusion	abstract[92]|abstract[93]	new[92]|giv[93]	_	_
11-34	1657-1660	and	abstract[92]	new[92]	_	_
11-35	1661-1664	low	abstract[92]|abstract[95]	new[92]|new[95]	coref	17-21[144_95]
11-36	1665-1671	oxygen	abstract[92]|substance|abstract[95]	new[92]|new|new[95]	coref	17-22
11-37	1672-1680	delivery	abstract[92]|abstract[95]	new[92]|new[95]	_	_
11-38	1681-1683	to	abstract[92]|abstract[95]	new[92]|new[95]	_	_
11-39	1684-1687	the	abstract[92]|abstract[95]|object[96]	new[92]|new[95]|new[96]	_	_
11-40	1688-1694	kidney	abstract[92]|abstract[95]|object[96]	new[92]|new[95]|new[96]	_	_
11-41	1695-1696	.	_	_	_	_

#Text=Furthermore , patients with ABO-i LT already receive a substantial amount of FFP transfusion for plasma exchange prior to surgery .
12-1	1697-1708	Furthermore	_	_	_	_
12-2	1709-1710	,	_	_	_	_
12-3	1711-1719	patients	person[97]	giv[97]	coref	13-27[114_97]
12-4	1720-1724	with	person[97]	giv[97]	_	_
12-5	1725-1730	ABO-i	person[97]|abstract[98]	giv[97]|giv[98]	coref	13-29[0_98]
12-6	1731-1733	LT	person[97]|abstract[98]	giv[97]|giv[98]	_	_
12-7	1734-1741	already	_	_	_	_
12-8	1742-1749	receive	_	_	_	_
12-9	1750-1751	a	abstract[99]	new[99]	_	_
12-10	1752-1763	substantial	abstract[99]	new[99]	_	_
12-11	1764-1770	amount	abstract[99]	new[99]	_	_
12-12	1771-1773	of	abstract[99]	new[99]	_	_
12-13	1774-1777	FFP	abstract[99]|substance|abstract[101]	new[99]|giv|giv[101]	coref|coref|coref|coref	13-1|14-13[121_101]|13-1|14-13[121_101]
12-14	1778-1789	transfusion	abstract[99]|abstract[101]	new[99]|giv[101]	_	_
12-15	1790-1793	for	abstract[99]|abstract[101]	new[99]|giv[101]	_	_
12-16	1794-1800	plasma	abstract[99]|abstract[101]|object|event[103]	new[99]|giv[101]|new|new[103]	coref|coref|coref|coref	23-6|23-5[183_103]|23-6|23-5[183_103]
12-17	1801-1809	exchange	abstract[99]|abstract[101]|event[103]	new[99]|giv[101]|new[103]	_	_
12-18	1810-1815	prior	_	_	_	_
12-19	1816-1818	to	_	_	_	_
12-20	1819-1826	surgery	event	giv	coref	13-13[109_0]
12-21	1827-1828	.	_	_	_	_

#Text=FFP has been reported to be a risk factor for AKI after surgery , including liver transplantation , and the risk of AKI may increase when patients with ABO-i LT receive intraoperative FFP transfusions .
13-1	1829-1832	FFP	substance	giv	coref	13-33
13-2	1833-1836	has	_	_	_	_
13-3	1837-1841	been	_	_	_	_
13-4	1842-1850	reported	_	_	_	_
13-5	1851-1853	to	_	_	_	_
13-6	1854-1856	be	_	_	_	_
13-7	1857-1858	a	abstract[107]	new[107]	_	_
13-8	1859-1863	risk	abstract|abstract[107]	giv|new[107]	coref	13-20[112_0]
13-9	1864-1870	factor	abstract[107]	new[107]	_	_
13-10	1871-1874	for	abstract[107]	new[107]	_	_
13-11	1875-1878	AKI	abstract[107]|place[108]	new[107]|giv[108]	coref	13-23[0_108]
13-12	1879-1884	after	abstract[107]|place[108]	new[107]|giv[108]	_	_
13-13	1885-1892	surgery	abstract[107]|place[108]|event[109]	new[107]|giv[108]|giv[109]	coref	16-24[0_109]
13-14	1893-1894	,	abstract[107]|place[108]|event[109]	new[107]|giv[108]|giv[109]	_	_
13-15	1895-1904	including	abstract[107]|place[108]|event[109]	new[107]|giv[108]|giv[109]	_	_
13-16	1905-1910	liver	abstract[107]|place[108]|event[109]|object|object[111]	new[107]|giv[108]|giv[109]|giv|giv[111]	coref|coref|coref|coref	15-13|15-13[130_111]|15-13|15-13[130_111]
13-17	1911-1926	transplantation	abstract[107]|place[108]|event[109]|object[111]	new[107]|giv[108]|giv[109]|giv[111]	_	_
13-18	1927-1928	,	_	_	_	_
13-19	1929-1932	and	_	_	_	_
13-20	1933-1936	the	abstract[112]	giv[112]	coref	15-8[0_112]
13-21	1937-1941	risk	abstract[112]	giv[112]	_	_
13-22	1942-1944	of	abstract[112]	giv[112]	_	_
13-23	1945-1948	AKI	abstract[112]|place	giv[112]|giv	coref	15-11[128_0]
13-24	1949-1952	may	_	_	_	_
13-25	1953-1961	increase	_	_	_	_
13-26	1962-1966	when	_	_	_	_
13-27	1967-1975	patients	person[114]	giv[114]	coref	14-19[0_114]
13-28	1976-1980	with	person[114]	giv[114]	_	_
13-29	1981-1986	ABO-i	person[114]|abstract	giv[114]|giv	coref	19-11[158_0]
13-30	1987-1989	LT	person[114]|abstract	giv[114]|giv	_	_
13-31	1990-1997	receive	_	_	_	_
13-32	1998-2012	intraoperative	abstract[118]	giv[118]	_	_
13-33	2013-2016	FFP	substance|abstract[118]	giv|giv[118]	coref	14-13
13-34	2017-2029	transfusions	abstract[118]	giv[118]	_	_
13-35	2030-2031	.	_	_	_	_

#Text=Furthermore , an inflammatory , allergic , and immunologic reaction triggered by FFP transfusion may be exacerbated when patients receive additional intraoperative FFP .
14-1	2032-2043	Furthermore	_	_	_	_
14-2	2044-2045	,	_	_	_	_
14-3	2046-2048	an	abstract[119]	new[119]	_	_
14-4	2049-2061	inflammatory	abstract[119]	new[119]	_	_
14-5	2062-2063	,	abstract[119]	new[119]	_	_
14-6	2064-2072	allergic	abstract[119]	new[119]	_	_
14-7	2073-2074	,	abstract[119]	new[119]	_	_
14-8	2075-2078	and	abstract[119]	new[119]	_	_
14-9	2079-2090	immunologic	abstract[119]	new[119]	_	_
14-10	2091-2099	reaction	abstract[119]	new[119]	_	_
14-11	2100-2109	triggered	_	_	_	_
14-12	2110-2112	by	_	_	_	_
14-13	2113-2116	FFP	substance|abstract[121]	giv|giv[121]	coref|coref|coref|coref	14-21[123_0]|15-1[125_121]|14-21[123_0]|15-1[125_121]
14-14	2117-2128	transfusion	abstract[121]	giv[121]	_	_
14-15	2129-2132	may	_	_	_	_
14-16	2133-2135	be	_	_	_	_
14-17	2136-2147	exacerbated	_	_	_	_
14-18	2148-2152	when	_	_	_	_
14-19	2153-2161	patients	person	giv	coref	19-8[157_0]
14-20	2162-2169	receive	_	_	_	_
14-21	2170-2180	additional	substance[123]	giv[123]	coref	18-14[0_123]
14-22	2181-2195	intraoperative	substance[123]	giv[123]	_	_
14-23	2196-2199	FFP	substance[123]	giv[123]	_	_
14-24	2200-2201	.	_	_	_	_

#Text=Red cell transfusion is also a well-known risk factor of AKI after liver transplantation .
15-1	2202-2205	Red	abstract[125]	giv[125]	coref	15-6[127_125]
15-2	2206-2210	cell	place|abstract[125]	new|giv[125]	coref	22-5
15-3	2211-2222	transfusion	abstract[125]	giv[125]	_	_
15-4	2223-2225	is	_	_	_	_
15-5	2226-2230	also	_	_	_	_
15-6	2231-2232	a	abstract[127]	giv[127]	coref	16-5[133_127]
15-7	2233-2243	well-known	abstract[127]	giv[127]	_	_
15-8	2244-2248	risk	abstract|abstract[127]	giv|giv[127]	_	_
15-9	2249-2255	factor	abstract[127]	giv[127]	_	_
15-10	2256-2258	of	abstract[127]	giv[127]	_	_
15-11	2259-2262	AKI	abstract[127]|place[128]	giv[127]|giv[128]	coref	16-22[0_128]
15-12	2263-2268	after	abstract[127]|place[128]	giv[127]|giv[128]	_	_
15-13	2269-2274	liver	abstract[127]|place[128]|object|event[130]	giv[127]|giv[128]|giv|giv[130]	coref|coref|coref|coref	25-19|25-19[204_130]|25-19|25-19[204_130]
15-14	2275-2290	transplantation	abstract[127]|place[128]|event[130]	giv[127]|giv[128]|giv[130]	_	_
15-15	2291-2292	.	_	_	_	_

#Text=The negative effect of pRBC transfusion is multifaceted and includes a systemic inflammatory response , which contributes to the development of AKI after surgery .
16-1	2293-2296	The	abstract[131]	new[131]	_	_
16-2	2297-2305	negative	abstract[131]	new[131]	_	_
16-3	2306-2312	effect	abstract[131]	new[131]	_	_
16-4	2313-2315	of	abstract[131]	new[131]	_	_
16-5	2316-2320	pRBC	abstract[131]|substance|abstract[133]	new[131]|giv|giv[133]	coref|coref|coref|coref	17-5[0_133]|18-12|17-5[0_133]|18-12
16-6	2321-2332	transfusion	abstract[131]|abstract[133]	new[131]|giv[133]	_	_
16-7	2333-2335	is	_	_	_	_
16-8	2336-2348	multifaceted	_	_	_	_
16-9	2349-2352	and	_	_	_	_
16-10	2353-2361	includes	_	_	_	_
16-11	2362-2363	a	abstract[134]	giv[134]	coref	18-6[0_134]
16-12	2364-2372	systemic	abstract[134]	giv[134]	_	_
16-13	2373-2385	inflammatory	abstract[134]	giv[134]	_	_
16-14	2386-2394	response	abstract[134]	giv[134]	_	_
16-15	2395-2396	,	_	_	_	_
16-16	2397-2402	which	_	_	_	_
16-17	2403-2414	contributes	_	_	_	_
16-18	2415-2417	to	_	_	_	_
16-19	2418-2421	the	event[135]	new[135]	_	_
16-20	2422-2433	development	event[135]	new[135]	_	_
16-21	2434-2436	of	event[135]	new[135]	_	_
16-22	2437-2440	AKI	event[135]|place	new[135]|giv	coref	18-20[153_0]
16-23	2441-2446	after	event[135]	new[135]	_	_
16-24	2447-2454	surgery	event[135]|event	new[135]|giv	coref	27-5
16-25	2455-2456	.	_	_	_	_

#Text=A large amount of transfusion reflects excessive surgical bleeding , which leads to renal hypoperfusion and ischemia , resulting in poor oxygen delivery .
17-1	2457-2458	A	abstract[138]	new[138]	_	_
17-2	2459-2464	large	abstract[138]	new[138]	_	_
17-3	2465-2471	amount	abstract[138]	new[138]	_	_
17-4	2472-2474	of	abstract[138]	new[138]	_	_
17-5	2475-2486	transfusion	abstract[138]|abstract	new[138]|giv	coref	18-14[151_0]
17-6	2487-2495	reflects	_	_	_	_
17-7	2496-2505	excessive	abstract[140]	new[140]	_	_
17-8	2506-2514	surgical	abstract[140]	new[140]	_	_
17-9	2515-2523	bleeding	abstract[140]	new[140]	_	_
17-10	2524-2525	,	_	_	_	_
17-11	2526-2531	which	_	_	_	_
17-12	2532-2537	leads	_	_	_	_
17-13	2538-2540	to	_	_	_	_
17-14	2541-2546	renal	abstract[141]	new[141]	_	_
17-15	2547-2560	hypoperfusion	abstract[141]	new[141]	_	_
17-16	2561-2564	and	_	_	_	_
17-17	2565-2573	ischemia	abstract	new	_	_
17-18	2574-2575	,	_	_	_	_
17-19	2576-2585	resulting	_	_	_	_
17-20	2586-2588	in	_	_	_	_
17-21	2589-2593	poor	abstract[144]	giv[144]	_	_
17-22	2594-2600	oxygen	substance|abstract[144]	giv|giv[144]	coref	26-18
17-23	2601-2609	delivery	abstract[144]	giv[144]	_	_
17-24	2610-2611	.	_	_	_	_

#Text=There was a dose – response relationship between the amount of pRBC and FFP transfusion and the risk of AKI in our study .
18-1	2612-2617	There	_	_	_	_
18-2	2618-2621	was	_	_	_	_
18-3	2622-2623	a	quantity[145]	new[145]	coref	28-7[221_145]
18-4	2624-2628	dose	quantity[145]	new[145]	_	_
18-5	2629-2630	–	_	_	_	_
18-6	2631-2639	response	abstract|abstract[147]	giv|new[147]	_	_
18-7	2640-2652	relationship	abstract[147]	new[147]	_	_
18-8	2653-2660	between	abstract[147]	new[147]	_	_
18-9	2661-2664	the	abstract[147]|abstract[148]	new[147]|new[148]	coref	24-3[189_148]
18-10	2665-2671	amount	abstract[147]|abstract[148]	new[147]|new[148]	_	_
18-11	2672-2674	of	abstract[147]|abstract[148]	new[147]|new[148]	_	_
18-12	2675-2679	pRBC	abstract[147]|abstract[148]|object	new[147]|new[148]|giv	coref	19-21
18-13	2680-2683	and	abstract[147]|abstract[148]	new[147]|new[148]	_	_
18-14	2684-2687	FFP	abstract[147]|abstract[148]|substance|abstract[151]	new[147]|new[148]|giv|giv[151]	coref|coref|coref|coref	19-21[162_151]|22-11|19-21[162_151]|22-11
18-15	2688-2699	transfusion	abstract[147]|abstract[148]|abstract[151]	new[147]|new[148]|giv[151]	_	_
18-16	2700-2703	and	_	_	_	_
18-17	2704-2707	the	abstract[152]	new[152]	coref	32-2[0_152]
18-18	2708-2712	risk	abstract[152]	new[152]	_	_
18-19	2713-2715	of	abstract[152]	new[152]	_	_
18-20	2716-2719	AKI	abstract[152]|place[153]	new[152]|giv[153]	coref	28-28[227_153]
18-21	2720-2722	in	abstract[152]|place[153]	new[152]|giv[153]	_	_
18-22	2723-2726	our	abstract[152]|place[153]|person|abstract[155]	new[152]|giv[153]|giv|giv[155]	ana|coref|ana|coref	21-2|30-6[238_155]|21-2|30-6[238_155]
18-23	2727-2732	study	abstract[152]|place[153]|abstract[155]	new[152]|giv[153]|giv[155]	_	_
18-24	2733-2734	.	_	_	_	_

#Text=However , it is not clear why the patients undergoing ABO-i LT were more susceptible to the deleterious effects of pRBC transfusion .
19-1	2735-2742	However	_	_	_	_
19-2	2743-2744	,	_	_	_	_
19-3	2745-2747	it	abstract	new	cata	19-3[0_159]
19-4	2748-2750	is	_	_	_	_
19-5	2751-2754	not	_	_	_	_
19-6	2755-2760	clear	_	_	_	_
19-7	2761-2764	why	abstract[159]	new[159]	_	_
19-8	2765-2768	the	person[157]|abstract[159]	giv[157]|new[159]	_	_
19-9	2769-2777	patients	person[157]|abstract[159]	giv[157]|new[159]	_	_
19-10	2778-2788	undergoing	abstract[159]	new[159]	_	_
19-11	2789-2794	ABO-i	abstract[158]|abstract[159]	giv[158]|new[159]	coref	24-7[190_158]
19-12	2795-2797	LT	abstract[158]|abstract[159]	giv[158]|new[159]	_	_
19-13	2798-2802	were	abstract[159]	new[159]	_	_
19-14	2803-2807	more	abstract[159]	new[159]	_	_
19-15	2808-2819	susceptible	abstract[159]	new[159]	_	_
19-16	2820-2822	to	_	_	_	_
19-17	2823-2826	the	abstract[160]	new[160]	_	_
19-18	2827-2838	deleterious	abstract[160]	new[160]	_	_
19-19	2839-2846	effects	abstract[160]	new[160]	_	_
19-20	2847-2849	of	abstract[160]	new[160]	_	_
19-21	2850-2854	pRBC	abstract[160]|substance|abstract[162]	new[160]|giv|giv[162]	coref|coref|coref|coref	20-9|20-9[166_162]|20-9|20-9[166_162]
19-22	2855-2866	transfusion	abstract[160]|abstract[162]	new[160]|giv[162]	_	_
19-23	2867-2868	.	_	_	_	_

#Text=Possible mechanisms include that the adverse effect of pRBC transfusion may be aggravated by a high isoagglutinin titer .
20-1	2869-2877	Possible	abstract[163]	new[163]	_	_
20-2	2878-2888	mechanisms	abstract[163]	new[163]	_	_
20-3	2889-2896	include	_	_	_	_
20-4	2897-2901	that	_	_	_	_
20-5	2902-2905	the	event[164]	new[164]	_	_
20-6	2906-2913	adverse	event[164]	new[164]	_	_
20-7	2914-2920	effect	event[164]	new[164]	_	_
20-8	2921-2923	of	event[164]	new[164]	_	_
20-9	2924-2928	pRBC	event[164]|substance|abstract[166]	new[164]|giv|giv[166]	coref|coref|coref|coref	22-4[177_166]|23-15|22-4[177_166]|23-15
20-10	2929-2940	transfusion	event[164]|abstract[166]	new[164]|giv[166]	_	_
20-11	2941-2944	may	_	_	_	_
20-12	2945-2947	be	_	_	_	_
20-13	2948-2958	aggravated	_	_	_	_
20-14	2959-2961	by	_	_	_	_
20-15	2962-2963	a	abstract[167]	giv[167]	coref	21-17[173_167]
20-16	2964-2968	high	abstract[167]	giv[167]	_	_
20-17	2969-2982	isoagglutinin	abstract[167]	giv[167]	_	_
20-18	2983-2988	titer	abstract[167]	giv[167]	_	_
20-19	2989-2990	.	_	_	_	_

#Text=Although we accounted for confounding factors through propensity-score-matching and multivariable analysis , we could not adjust the isoagglutinin titer due to a lack of data .
21-1	2991-2999	Although	_	_	_	_
21-2	3000-3002	we	person	giv	ana	21-13
21-3	3003-3012	accounted	_	_	_	_
21-4	3013-3016	for	_	_	_	_
21-5	3017-3028	confounding	_	_	_	_
21-6	3029-3036	factors	abstract	giv	_	_
21-7	3037-3044	through	_	_	_	_
21-8	3045-3070	propensity-score-matching	abstract|abstract[171]	new|giv[171]	coref|coref	35-13[262_171]|35-13[262_171]
21-9	3071-3074	and	abstract[171]	giv[171]	_	_
21-10	3075-3088	multivariable	abstract[171]	giv[171]	_	_
21-11	3089-3097	analysis	abstract[171]	giv[171]	_	_
21-12	3098-3099	,	_	_	_	_
21-13	3100-3102	we	person	giv	ana	24-10
21-14	3103-3108	could	_	_	_	_
21-15	3109-3112	not	_	_	_	_
21-16	3113-3119	adjust	_	_	_	_
21-17	3120-3123	the	abstract[173]	giv[173]	_	_
21-18	3124-3137	isoagglutinin	abstract[173]	giv[173]	_	_
21-19	3138-3143	titer	abstract[173]	giv[173]	_	_
21-20	3144-3147	due	abstract[173]	giv[173]	_	_
21-21	3148-3150	to	_	_	_	_
21-22	3151-3152	a	quantity[174]	new[174]	_	_
21-23	3153-3157	lack	quantity[174]	new[174]	_	_
21-24	3158-3160	of	quantity[174]	new[174]	_	_
21-25	3161-3165	data	quantity[174]|abstract	new[174]|new	_	_
21-26	3166-3167	.	_	_	_	_

#Text=In addition , red cell transfusion is closely related to FFP transfusion .
22-1	3168-3170	In	_	_	_	_
22-2	3171-3179	addition	_	_	_	_
22-3	3180-3181	,	_	_	_	_
22-4	3182-3185	red	abstract[177]	giv[177]	coref	22-11[179_177]
22-5	3186-3190	cell	place|abstract[177]	giv|giv[177]	coref	27-2
22-6	3191-3202	transfusion	abstract[177]	giv[177]	_	_
22-7	3203-3205	is	_	_	_	_
22-8	3206-3213	closely	_	_	_	_
22-9	3214-3221	related	_	_	_	_
22-10	3222-3224	to	_	_	_	_
22-11	3225-3228	FFP	substance|abstract[179]	giv|giv[179]	coref|coref|coref|coref	23-2|23-1[181_179]|23-2|23-1[181_179]
22-12	3229-3240	transfusion	abstract[179]	giv[179]	_	_
22-13	3241-3242	.	_	_	_	_

#Text=Cumulative FFP transfusion after preoperative plasma exchange could be the leading cause , and pRBC transfusion could be a simple association .
23-1	3243-3253	Cumulative	abstract[181]	giv[181]	coref	23-15[186_181]
23-2	3254-3257	FFP	substance|abstract[181]	giv|giv[181]	_	_
23-3	3258-3269	transfusion	abstract[181]	giv[181]	_	_
23-4	3270-3275	after	_	_	_	_
23-5	3276-3288	preoperative	abstract[183]	giv[183]	coref	23-10[184_183]
23-6	3289-3295	plasma	substance|abstract[183]	giv|giv[183]	_	_
23-7	3296-3304	exchange	abstract[183]	giv[183]	_	_
23-8	3305-3310	could	_	_	_	_
23-9	3311-3313	be	_	_	_	_
23-10	3314-3317	the	abstract[184]	giv[184]	_	_
23-11	3318-3325	leading	abstract[184]	giv[184]	_	_
23-12	3326-3331	cause	abstract[184]	giv[184]	_	_
23-13	3332-3333	,	abstract[184]	giv[184]	_	_
23-14	3334-3337	and	abstract[184]	giv[184]	_	_
23-15	3338-3342	pRBC	abstract[184]|substance|abstract[186]	giv[184]|giv|giv[186]	coref|coref|coref|coref	23-19[187_186]|25-12|23-19[187_186]|25-12
23-16	3343-3354	transfusion	abstract[184]|abstract[186]	giv[184]|giv[186]	_	_
23-17	3355-3360	could	abstract[184]	giv[184]	_	_
23-18	3361-3363	be	abstract[184]	giv[184]	_	_
23-19	3364-3365	a	abstract[184]|abstract[187]	giv[184]|giv[187]	coref	24-4[0_187]
23-20	3366-3372	simple	abstract[184]|abstract[187]	giv[184]|giv[187]	_	_
23-21	3373-3384	association	abstract[184]|abstract[187]	giv[184]|giv[187]	_	_
23-22	3385-3386	.	_	_	_	_

#Text=To reduce the transfusion amount in ABO-i LT , we could adopt a restrictive transfusion policy by decreasing the transfusion threshold .
24-1	3387-3389	To	_	_	_	_
24-2	3390-3396	reduce	_	_	_	_
24-3	3397-3400	the	abstract[189]	giv[189]	coref	28-16[224_189]
24-4	3401-3412	transfusion	abstract|abstract[189]	giv|giv[189]	coref	24-15
24-5	3413-3419	amount	abstract[189]	giv[189]	_	_
24-6	3420-3422	in	_	_	_	_
24-7	3423-3428	ABO-i	abstract[190]	giv[190]	coref	31-6[243_190]
24-8	3429-3431	LT	abstract[190]	giv[190]	_	_
24-9	3432-3433	,	_	_	_	_
24-10	3434-3436	we	person	giv	ana	25-16
24-11	3437-3442	could	_	_	_	_
24-12	3443-3448	adopt	_	_	_	_
24-13	3449-3450	a	abstract[193]	new[193]	_	_
24-14	3451-3462	restrictive	abstract[193]	new[193]	_	_
24-15	3463-3474	transfusion	abstract|abstract[193]	giv|new[193]	coref	24-20
24-16	3475-3481	policy	abstract[193]	new[193]	_	_
24-17	3482-3484	by	_	_	_	_
24-18	3485-3495	decreasing	_	_	_	_
24-19	3496-3499	the	abstract[195]	new[195]	coref	25-11[200_195]
24-20	3500-3511	transfusion	abstract|abstract[195]	giv|new[195]	coref	25-8[197_0]
24-21	3512-3521	threshold	abstract[195]	new[195]	_	_
24-22	3522-3523	.	_	_	_	_

#Text=Although there is no established consensus regarding intraoperative transfusion , the pRBC transfusion threshold in our institution during liver transplantation was around 20 % in hematocrit .
25-1	3524-3532	Although	_	_	_	_
25-2	3533-3538	there	_	_	_	_
25-3	3539-3541	is	_	_	_	_
25-4	3542-3544	no	abstract[196]	new[196]	_	_
25-5	3545-3556	established	abstract[196]	new[196]	_	_
25-6	3557-3566	consensus	abstract[196]	new[196]	_	_
25-7	3567-3576	regarding	_	_	_	_
25-8	3577-3591	intraoperative	abstract[197]	giv[197]	coref	25-13[0_197]
25-9	3592-3603	transfusion	abstract[197]	giv[197]	_	_
25-10	3604-3605	,	_	_	_	_
25-11	3606-3609	the	abstract[200]	giv[200]	coref	25-22[205_200]
25-12	3610-3614	pRBC	abstract|abstract[200]	giv|giv[200]	_	_
25-13	3615-3626	transfusion	abstract|abstract[200]	giv|giv[200]	coref	27-1[214_0]
25-14	3627-3636	threshold	abstract[200]	giv[200]	_	_
25-15	3637-3639	in	abstract[200]	giv[200]	_	_
25-16	3640-3643	our	abstract[200]|person|organization[202]	giv[200]|giv|new[202]	ana|ana	30-6|30-6
25-17	3644-3655	institution	abstract[200]|organization[202]	giv[200]|new[202]	_	_
25-18	3656-3662	during	abstract[200]|organization[202]	giv[200]|new[202]	_	_
25-19	3663-3668	liver	abstract[200]|organization[202]|object|event[204]	giv[200]|new[202]|giv|giv[204]	_	_
25-20	3669-3684	transplantation	abstract[200]|organization[202]|event[204]	giv[200]|new[202]|giv[204]	_	_
25-21	3685-3688	was	_	_	_	_
25-22	3689-3695	around	abstract[205]	giv[205]	coref	26-1[207_205]
25-23	3696-3698	20	abstract[205]	giv[205]	_	_
25-24	3699-3700	%	abstract[205]	giv[205]	_	_
25-25	3701-3703	in	abstract[205]	giv[205]	_	_
25-26	3704-3714	hematocrit	abstract[205]|abstract	giv[205]|new	coref	27-12[216_0]
25-27	3715-3716	.	_	_	_	_

#Text=This threshold could be lowered further depending on the baseline status of recipients or the mixed venous oxygen concentrations .
26-1	3717-3721	This	abstract[207]	giv[207]	_	_
26-2	3722-3731	threshold	abstract[207]	giv[207]	_	_
26-3	3732-3737	could	_	_	_	_
26-4	3738-3740	be	_	_	_	_
26-5	3741-3748	lowered	_	_	_	_
26-6	3749-3756	further	_	_	_	_
26-7	3757-3766	depending	_	_	_	_
26-8	3767-3769	on	_	_	_	_
26-9	3770-3773	the	abstract[208]	new[208]	_	_
26-10	3774-3782	baseline	abstract[208]	new[208]	_	_
26-11	3783-3789	status	abstract[208]	new[208]	_	_
26-12	3790-3792	of	abstract[208]	new[208]	_	_
26-13	3793-3803	recipients	abstract[208]|person	new[208]|new	_	_
26-14	3804-3806	or	abstract[208]	new[208]	_	_
26-15	3807-3810	the	abstract[208]|animal[212]	new[208]|new[212]	_	_
26-16	3811-3816	mixed	abstract[208]|animal[212]	new[208]|new[212]	_	_
26-17	3817-3823	venous	abstract[208]|substance|animal[212]	new[208]|new|new[212]	_	_
26-18	3824-3830	oxygen	abstract[208]|substance|animal[212]	new[208]|giv|new[212]	_	_
26-19	3831-3845	concentrations	abstract[208]|animal[212]	new[208]|new[212]	_	_
26-20	3846-3847	.	_	_	_	_

#Text=Red cell transfusion during surgery could possibly be reduced by optimizing baseline hematocrit before surgery through the administration of erythropoietin .
27-1	3848-3851	Red	abstract[214]	giv[214]	coref	28-17[0_214]
27-2	3852-3856	cell	place|abstract[214]	giv|giv[214]	_	_
27-3	3857-3868	transfusion	abstract[214]	giv[214]	_	_
27-4	3869-3875	during	abstract[214]	giv[214]	_	_
27-5	3876-3883	surgery	abstract[214]|event	giv[214]|giv	coref	27-15
27-6	3884-3889	could	_	_	_	_
27-7	3890-3898	possibly	_	_	_	_
27-8	3899-3901	be	_	_	_	_
27-9	3902-3909	reduced	_	_	_	_
27-10	3910-3912	by	_	_	_	_
27-11	3913-3923	optimizing	_	_	_	_
27-12	3924-3932	baseline	abstract[216]	giv[216]	_	_
27-13	3933-3943	hematocrit	abstract[216]	giv[216]	_	_
27-14	3944-3950	before	_	_	_	_
27-15	3951-3958	surgery	event	giv	coref	28-20[225_0]
27-16	3959-3966	through	_	_	_	_
27-17	3967-3970	the	event[218]	new[218]	_	_
27-18	3971-3985	administration	event[218]	new[218]	_	_
27-19	3986-3988	of	event[218]	new[218]	_	_
27-20	3989-4003	erythropoietin	event[218]|substance	new[218]|new	coref	28-13
27-21	4004-4005	.	_	_	_	_

#Text=A previous randomized trial reported that a preoperative single intravenous dose of erythropoietin could reduce the transfusion amount during cardiac surgery , thereby reducing the incidence of postoperative AKI .
28-1	4006-4007	A	abstract[220]	new[220]	_	_
28-2	4008-4016	previous	abstract[220]	new[220]	_	_
28-3	4017-4027	randomized	abstract[220]	new[220]	_	_
28-4	4028-4033	trial	abstract[220]	new[220]	_	_
28-5	4034-4042	reported	_	_	_	_
28-6	4043-4047	that	_	_	_	_
28-7	4048-4049	a	quantity[221]	giv[221]	_	_
28-8	4050-4062	preoperative	quantity[221]	giv[221]	_	_
28-9	4063-4069	single	quantity[221]	giv[221]	_	_
28-10	4070-4081	intravenous	quantity[221]	giv[221]	_	_
28-11	4082-4086	dose	quantity[221]	giv[221]	_	_
28-12	4087-4089	of	quantity[221]	giv[221]	_	_
28-13	4090-4104	erythropoietin	quantity[221]|substance	giv[221]|giv	_	_
28-14	4105-4110	could	_	_	_	_
28-15	4111-4117	reduce	_	_	_	_
28-16	4118-4121	the	abstract[224]	giv[224]	_	_
28-17	4122-4133	transfusion	abstract|abstract[224]	giv|giv[224]	coref	29-6
28-18	4134-4140	amount	abstract[224]	giv[224]	_	_
28-19	4141-4147	during	abstract[224]	giv[224]	_	_
28-20	4148-4155	cardiac	abstract[224]|event[225]	giv[224]|giv[225]	_	_
28-21	4156-4163	surgery	abstract[224]|event[225]	giv[224]|giv[225]	_	_
28-22	4164-4165	,	_	_	_	_
28-23	4166-4173	thereby	_	_	_	_
28-24	4174-4182	reducing	_	_	_	_
28-25	4183-4186	the	abstract[226]	new[226]	_	_
28-26	4187-4196	incidence	abstract[226]	new[226]	_	_
28-27	4197-4199	of	abstract[226]	new[226]	_	_
28-28	4200-4213	postoperative	abstract[226]|place[227]	new[226]|giv[227]	coref	30-4[236_227]
28-29	4214-4217	AKI	abstract[226]|place[227]	new[226]|giv[227]	_	_
28-30	4218-4219	.	_	_	_	_

#Text=In addition , to reduce transfusion requirements , the intraoperative use of vasopressin was reported to reduce surgical bleeding through selective splanchnic vasoconstriction and by reducing portal blood flow .
29-1	4220-4222	In	_	_	_	_
29-2	4223-4231	addition	_	_	_	_
29-3	4232-4233	,	_	_	_	_
29-4	4234-4236	to	_	_	_	_
29-5	4237-4243	reduce	_	_	_	_
29-6	4244-4255	transfusion	abstract|abstract[229]	giv|new[229]	_	_
29-7	4256-4268	requirements	abstract[229]	new[229]	_	_
29-8	4269-4270	,	_	_	_	_
29-9	4271-4274	the	abstract[230]	new[230]	_	_
29-10	4275-4289	intraoperative	abstract[230]	new[230]	_	_
29-11	4290-4293	use	abstract[230]	new[230]	_	_
29-12	4294-4296	of	abstract[230]	new[230]	_	_
29-13	4297-4308	vasopressin	abstract[230]|substance	new[230]|new	_	_
29-14	4309-4312	was	_	_	_	_
29-15	4313-4321	reported	_	_	_	_
29-16	4322-4324	to	_	_	_	_
29-17	4325-4331	reduce	_	_	_	_
29-18	4332-4340	surgical	_	_	_	_
29-19	4341-4349	bleeding	_	_	_	_
29-20	4350-4357	through	_	_	_	_
29-21	4358-4367	selective	abstract[232]	new[232]	_	_
29-22	4368-4378	splanchnic	abstract[232]	new[232]	_	_
29-23	4379-4395	vasoconstriction	abstract[232]	new[232]	_	_
29-24	4396-4399	and	_	_	_	_
29-25	4400-4402	by	_	_	_	_
29-26	4403-4411	reducing	_	_	_	_
29-27	4412-4418	portal	abstract[234]	new[234]	_	_
29-28	4419-4424	blood	substance|abstract[234]	new|new[234]	_	_
29-29	4425-4429	flow	abstract[234]	new[234]	_	_
29-30	4430-4431	.	_	_	_	_

#Text=The incidence of AKI in our study was within the range reported in previous literature .
30-1	4432-4435	The	abstract[235]	new[235]	_	_
30-2	4436-4445	incidence	abstract[235]	new[235]	_	_
30-3	4446-4448	of	abstract[235]	new[235]	_	_
30-4	4449-4452	AKI	abstract[235]|place[236]	new[235]|giv[236]	coref	31-4[242_236]
30-5	4453-4455	in	abstract[235]|place[236]	new[235]|giv[236]	_	_
30-6	4456-4459	our	abstract[235]|place[236]|person|abstract[238]	new[235]|giv[236]|giv|giv[238]	coref|ana|coref|ana	31-12[244_238]|35-13|31-12[244_238]|35-13
30-7	4460-4465	study	abstract[235]|place[236]|abstract[238]	new[235]|giv[236]|giv[238]	_	_
30-8	4466-4469	was	_	_	_	_
30-9	4470-4476	within	_	_	_	_
30-10	4477-4480	the	abstract[239]	new[239]	_	_
30-11	4481-4486	range	abstract[239]	new[239]	_	_
30-12	4487-4495	reported	_	_	_	_
30-13	4496-4498	in	_	_	_	_
30-14	4499-4507	previous	abstract[240]	new[240]	coref	32-16[250_240]
30-15	4508-4518	literature	abstract[240]	new[240]	_	_
30-16	4519-4520	.	_	_	_	_

#Text=The incidence of AKI in ABO-i LT was also similar to a previous study .
31-1	4521-4524	The	abstract[241]	new[241]	_	_
31-2	4525-4534	incidence	abstract[241]	new[241]	_	_
31-3	4535-4537	of	abstract[241]	new[241]	_	_
31-4	4538-4541	AKI	abstract[241]|place[242]	new[241]|giv[242]	coref	32-5[0_242]
31-5	4542-4544	in	abstract[241]|place[242]	new[241]|giv[242]	_	_
31-6	4545-4550	ABO-i	abstract[241]|place[242]|abstract[243]	new[241]|giv[242]|giv[243]	coref	32-8[248_243]
31-7	4551-4553	LT	abstract[241]|place[242]|abstract[243]	new[241]|giv[242]|giv[243]	_	_
31-8	4554-4557	was	_	_	_	_
31-9	4558-4562	also	_	_	_	_
31-10	4563-4570	similar	_	_	_	_
31-11	4571-4573	to	_	_	_	_
31-12	4574-4575	a	abstract[244]	giv[244]	_	_
31-13	4576-4584	previous	abstract[244]	giv[244]	_	_
31-14	4585-4590	study	abstract[244]	giv[244]	_	_
31-15	4591-4592	.	_	_	_	_

#Text=The risk factors of AKI other than ABO-i LT were mostly consistent with those of the previous literature .
32-1	4593-4596	The	abstract[246]	new[246]	_	_
32-2	4597-4601	risk	abstract|abstract[246]	giv|new[246]	_	_
32-3	4602-4609	factors	abstract[246]	new[246]	_	_
32-4	4610-4612	of	abstract[246]	new[246]	_	_
32-5	4613-4616	AKI	abstract[246]|place	new[246]|giv	coref	33-9[253_0]
32-6	4617-4622	other	abstract[246]	new[246]	_	_
32-7	4623-4627	than	_	_	_	_
32-8	4628-4633	ABO-i	abstract[248]	giv[248]	ana	32-14[249_248]
32-9	4634-4636	LT	abstract[248]	giv[248]	_	_
32-10	4637-4641	were	_	_	_	_
32-11	4642-4648	mostly	_	_	_	_
32-12	4649-4659	consistent	_	_	_	_
32-13	4660-4664	with	_	_	_	_
32-14	4665-4670	those	abstract[249]	giv[249]	_	_
32-15	4671-4673	of	abstract[249]	giv[249]	_	_
32-16	4674-4677	the	abstract[249]|abstract[250]	giv[249]|giv[250]	_	_
32-17	4678-4686	previous	abstract[249]|abstract[250]	giv[249]|giv[250]	_	_
32-18	4687-4697	literature	abstract[249]|abstract[250]	giv[249]|giv[250]	_	_
32-19	4698-4699	.	_	_	_	_

#Text=The preoperative hemoglobin level was independently associated with post-transplant AKI .
33-1	4700-4703	The	abstract[252]	new[252]	_	_
33-2	4704-4716	preoperative	abstract[252]	new[252]	_	_
33-3	4717-4727	hemoglobin	place|abstract[252]	new|new[252]	_	_
33-4	4728-4733	level	abstract[252]	new[252]	_	_
33-5	4734-4737	was	_	_	_	_
33-6	4738-4751	independently	_	_	_	_
33-7	4752-4762	associated	_	_	_	_
33-8	4763-4767	with	_	_	_	_
33-9	4768-4783	post-transplant	place[253]	giv[253]	coref	34-13[0_253]
33-10	4784-4787	AKI	place[253]	giv[253]	_	_
33-11	4788-4789	.	_	_	_	_

#Text=The MELD score has been consistently reported to be a predictor of AKI .
34-1	4790-4793	The	abstract[255]	new[255]	_	_
34-2	4794-4798	MELD	abstract|abstract[255]	new|new[255]	_	_
34-3	4799-4804	score	abstract[255]	new[255]	_	_
34-4	4805-4808	has	_	_	_	_
34-5	4809-4813	been	_	_	_	_
34-6	4814-4826	consistently	_	_	_	_
34-7	4827-4835	reported	_	_	_	_
34-8	4836-4838	to	_	_	_	_
34-9	4839-4841	be	_	_	_	_
34-10	4842-4843	a	abstract[256]	new[256]	_	_
34-11	4844-4853	predictor	abstract[256]	new[256]	_	_
34-12	4854-4856	of	abstract[256]	new[256]	_	_
34-13	4857-4860	AKI	abstract[256]|place	new[256]|giv	coref	35-11[260_0]
34-14	4861-4862	.	_	_	_	_

#Text=Ischemic time was not identified as an independent predictor of AKI in our analysis , which could have been due to the relatively short ischemic time of LDLT .
35-1	4863-4871	Ischemic	abstract|time[259]	new|new[259]	coref|coref	35-25|35-25
35-2	4872-4876	time	time[259]	new[259]	_	_
35-3	4877-4880	was	_	_	_	_
35-4	4881-4884	not	_	_	_	_
35-5	4885-4895	identified	_	_	_	_
35-6	4896-4898	as	_	_	_	_
35-7	4899-4901	an	_	_	_	_
35-8	4902-4913	independent	_	_	_	_
35-9	4914-4923	predictor	_	_	_	_
35-10	4924-4926	of	_	_	_	_
35-11	4927-4930	AKI	place[260]	giv[260]	_	_
35-12	4931-4933	in	place[260]	giv[260]	_	_
35-13	4934-4937	our	place[260]|person|abstract[262]	giv[260]|giv|giv[262]	_	_
35-14	4938-4946	analysis	place[260]|abstract[262]	giv[260]|giv[262]	_	_
35-15	4947-4948	,	_	_	_	_
35-16	4949-4954	which	_	_	_	_
35-17	4955-4960	could	_	_	_	_
35-18	4961-4965	have	_	_	_	_
35-19	4966-4970	been	_	_	_	_
35-20	4971-4974	due	_	_	_	_
35-21	4975-4977	to	_	_	_	_
35-22	4978-4981	the	abstract[264]	new[264]	_	_
35-23	4982-4992	relatively	abstract[264]	new[264]	_	_
35-24	4993-4998	short	abstract[264]	new[264]	_	_
35-25	4999-5007	ischemic	abstract|abstract[264]	giv|new[264]	_	_
35-26	5008-5012	time	abstract[264]	new[264]	_	_
35-27	5013-5015	of	abstract[264]	new[264]	_	_
35-28	5016-5020	LDLT	abstract[264]|abstract	new[264]|new	_	_
35-29	5021-5022	.	_	_	_	_
